Endothelin receptor blockade potentiates FasL-induced apoptosis in colon carcinoma cells via the protein kinase C-pathway
- PMID: 11078419
- DOI: 10.1097/00005344-200036051-00103
Endothelin receptor blockade potentiates FasL-induced apoptosis in colon carcinoma cells via the protein kinase C-pathway
Abstract
An imbalance between proliferation and apoptosis is important in tumor progression. Endothelin-1 (ET-1) has vasoconstricting and mitogenic activities and may be involved in apoptosis regulation. We found that ET-1 and FasL systems were colocalized in human colon tumors and that ET-1 was secreted by human (HT-29, SW480) and rat (PROb, REGb) colon carcinoma cell lines. Bosentan, a mixed endothelin-A- and -B- (ET(A)/ET(B)) receptor antagonist, potentiated FasL- (APO-1, CD95) induced apoptosis in these cells. The specific inhibition of enzymes involved in ceramide production did not restore survival of cells exposed to FasL and bosentan. Inhibition of PKC with bisindolylmaleimide IX enhanced FasL-induced apoptosis in HT-29, PROb and REGb cells in the absence of bosentan. These results suggest that ET-1 is an autocrine survival factor able to protect colon carcinoma cells against FasL-induced apoptosis, involving the protein kinase C (PKC) but not the sphingomyelin-ceramide signaling transduction pathways.
Similar articles
-
Endothelin-receptor antagonists are proapoptotic and antiproliferative in human colon cancer cells.Br J Cancer. 2003 Mar 10;88(5):788-95. doi: 10.1038/sj.bjc.6600810. Br J Cancer. 2003. PMID: 12618891 Free PMC article.
-
Endothelin receptor blockade potentiates FasL-induced apoptosis in rat colon carcinoma cells.Int J Cancer. 2000 Apr 15;86(2):182-7. doi: 10.1002/(sici)1097-0215(20000415)86:2<182::aid-ijc6>3.0.co;2-g. Int J Cancer. 2000. PMID: 10738244
-
Targeting the endothelin axis in human melanoma: combination of endothelin receptor antagonism and alkylating agents.Exp Biol Med (Maywood). 2006 Jun;231(6):1111-9. Exp Biol Med (Maywood). 2006. PMID: 16741059
-
Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict.Ann N Y Acad Sci. 2000 Jun;910:178-92; discussion 193-5. doi: 10.1111/j.1749-6632.2000.tb06708.x. Ann N Y Acad Sci. 2000. PMID: 10911913 Review.
-
On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.Leuk Lymphoma. 1998 Nov;31(5-6):477-90. doi: 10.3109/10428199809057607. Leuk Lymphoma. 1998. PMID: 9922038 Review.
Cited by
-
Endothelin-1 inhibits apoptosis in prostate cancer.Neoplasia. 2005 Jul;7(7):631-7. doi: 10.1593/neo.04787. Neoplasia. 2005. PMID: 16026642 Free PMC article.
-
Isoforms of endothelin-converting enzyme-1 (ECE-1) have opposing effects on prostate cancer cell invasion.Br J Cancer. 2008 Oct 7;99(7):1114-20. doi: 10.1038/sj.bjc.6604631. Epub 2008 Sep 9. Br J Cancer. 2008. PMID: 18781169 Free PMC article.
-
Impact of pre-angiogenic factors on the treatment effect of bevacizumab in patients with metastatic colorectal cancer.Med Oncol. 2014 Apr;31(4):905. doi: 10.1007/s12032-014-0905-8. Epub 2014 Mar 5. Med Oncol. 2014. PMID: 24596030
-
Endothelin-A receptor blockade slows the progression of renal injury in experimental renovascular disease.Am J Physiol Renal Physiol. 2011 Jul;301(1):F218-25. doi: 10.1152/ajprenal.00089.2011. Epub 2011 Apr 6. Am J Physiol Renal Physiol. 2011. PMID: 21478482 Free PMC article.
-
Endothelin-receptor antagonists are proapoptotic and antiproliferative in human colon cancer cells.Br J Cancer. 2003 Mar 10;88(5):788-95. doi: 10.1038/sj.bjc.6600810. Br J Cancer. 2003. PMID: 12618891 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials